Evidence map›Paper›PMID 33941580›Full record

ArticleInfection and immunity2021

Comparative Pathogenomics of

J R Clark, A M Maresso

Open access · hybridAbstract read
In one paragraph

Article in Infection and immunity, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Research Progress on perinatalFrontiers in microbiology · 2026
    Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Comparative Genomic Analyses ofJournal of microbiology and biotechnology · 2024
    Article
  14. DistinctbioRxiv : the preprint server for biology · 2024
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

J R ClarkBCM Tailor Labs, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
A M MaressoBCM Tailor Labs, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA.
Baylor College of Medicine · US

Funding

Viral Diversity and Pathogenicity in Mucosal Respiratory and Gastrointestinal DiseaseU19AI144297 · NIAID · BAYLOR COLLEGE OF MEDICINE · PI MARESSO, ANTHONY W · 2019 to 2024
$30.1M
NIAID NIH HHS U19 AI144297
6 · The paper itself

Abstract

Comparative genomics of bacterial pathogens has been useful for revealing potential virulence factors. Escherichia coli is a significant cause of human morbidity and mortality worldwide but can also exist as a commensal in the human gastrointestinal tract. With many sequenced genomes, it has served as a model organism for comparative genomic studies to understand the link between genetic content and potential for virulence. To date, however, no comprehensive analysis of its complete "virulome" has been performed for the purpose of identifying universal or pathotype-specific targets for vaccine development. Here, we describe the construction of a pathotype database of 107 well-characterized completely sequenced pathogenic and nonpathogenic E. coli strains, which we annotated for major virulence factors (VFs). The data are cross referenced for patterns against pathotype, phylogroup, and sequence type, and the results were verified against all 1,348 complete E. coli chromosomes in the NCBI RefSeq database. Our results demonstrate that phylogroup drives many of the "pathotype-associated" VFs, and ExPEC-associated VFs are found predominantly within the B2/D/F/G phylogenetic clade, suggesting that these phylogroups are better adapted to infect human hosts. Finally, we used this information to propose polyvalent vaccine targets with specificity toward extraintestinal strains, targeting key invasive strategies, including immune evasion (group 2 capsule), iron acquisition (FyuA, IutA, and Sit), adherence (SinH, Afa, Pap, Sfa, and Iha), and toxins (Usp, Sat, Vat, Cdt, Cnf1, and HlyA). While many of these targets have been proposed before, this work is the first to examine their pathotype and phylogroup distribution and how they may be targeted together to prevent disease.

Indexed as

Genome, BacterialGenomicsAnimalsBacterial VaccinesEscherichia coliEscherichia coli InfectionsEscherichia coli ProteinsExtraintestinal Pathogenic Escherichia coliGenes, BacterialHumansVaccines, CombinedVirulenceVirulence FactorsBacterial VaccinesEscherichia coli ProteinsVaccines, CombinedVirulence Factorscomparative genomicsenteric pathogensEscherichia coliExPECgenomicsInPECpathogenesispathogenomicsvaccine developmentvaccinesvirulence factors

Identifiers

PMID33941580
PMCPMC8281228
OpenAlexW3158979294

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.